Cancer Vaccines and Immunotherapy: Latest Advances, Limitations and Prospects
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: 28 February 2025 | Viewed by 163
Special Issue Editors
2. Biomedical Research Center, School of Science, Engineering and Environment, University of Salford, Manchester, UK
3. College of Health Sciences, Abu Dhabi University, Abu Dhabi, United Arab Emirates
Interests: immunology; cancer immunotherapy; tumor immunology; T regulatory cells
Interests: predictive/prognostic tumor biomarkers; tumor-host immune interactions to immunotherapeutic strategies; immune-monitoring tools of novel immune-modulators and cancer antigen-specific immune cells; translational and precision medicine tools such as liquid biopsy as biomarkers of response; immune checkpoint inhibitors and immune modulatory vaccines as therapeutic targets; lung cancer, gastric cancer, head and neck cancers
Special Issue Information
Dear Colleagues,
We invite you to participate in this Special Issue dedicated to the latest advancements and future prospects in cancer vaccines and immunotherapy. This Special Issue aims to enhance our understanding of the potential of cancer vaccines and immunotherapy, as well as their limitations, and provide insights for improving their effectiveness. We welcome original research articles and reviews covering a range of topics, including the latest advances in cancer vaccines and immunotherapy, their impact on the immune system and the response to cancer cells, and their combination with other cancer therapies. We also welcome studies based on the effectiveness of these treatments in cancer management, their potential for preventing cancer recurrence, as well as any potential side effects and risks associated with them. Additionally, we encourage submissions addressing the challenges and limitations of using cancer vaccines and immunotherapy in clinical practice and offering approaches to improve their efficacy and accessibility to cancer patients. We look forward to receiving your valuable contributions to this Special Issue.
Prof. Dr. Eyad Elkord
Dr. Afsheen Raza
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer
- tumor microenvironment
- tumor immunotherapy
- therapy
- cancer vaccines
- combination therapy
- tumor immune microenvironment
- advanced therapies
- biomarkers
